News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Researchers at the University of Alberta, Canada say a synthetic version of the extinct horsepox virus could yield more efficient protein expression systems and better vaccines.
The US FDA has promised to review Spark Therapeutics’ candidate vision loss gene therapy Luxturna by next January.
Emergent BioSolutions will pay up to $125m (€108m) for Sanofi’s smallpox vaccine ACAM2000 in a deal that includes a plant and 10-year supply contract with the US Government.
BiondVax Pharmaceuticals Ltd has leased space for a manufacturing plant with capacity to make tens of millions of doses of its flu vaccine, M-001.